Meeting
2012 Gastrointestinal Cancers Symposium
Alternative sequencing of FOLFIRI or mFOLFOX6 with erlotinib in the second-line treatment of metastatic colorectal cancer (mCRC): An ongoing phase II trial.
Authors
Charles D. Lopez
Oregon Health and Science University, Portland, OR
Charles D. Lopez , Gina M. Vaccaro , Kerstin M Kampa-Schittenhelm , John M. Strother , Andrea Burt , Jeff Masterson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon and Rectum
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Clinical Trial Registration Number
NCT00642746
Citation
J Clin Oncol 30, 2012 (suppl 4; abstr 507)
DOI
10.1200/jco.2012.30.4_suppl.507
Abstract #
507
Poster Bd #
C30
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Phase II study of panitumumab with irinotecan for patients with KRAS wild-type metastatic colorectal cancer (MCRC) refractory to standard chemotherapy: A GERCOR study.
First Author: B. Chibaudel
Poster
2019 ASCO Annual Meeting
Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC.
First Author: Jamie E. Chaft
Poster
2016 ASCO Annual Meeting
Bevacizumab or cetuximab plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wtkras metastatic colorectal cancer: A randomized phase II study (Prodige 18 –UNICANCER GI).
First Author: Sandrine Hiret
Poster
2011 ASCO Annual Meeting
A randomized phase III trial on maintenance treatment with bevacizumab (bev) alone or in combination with erlotinib (erlo) after chemotherapy and bev in metastatic colorectal cancer (mCRC).
First Author: A. Johnsson